Peptides DB
Research-centric peptide and protocol reference hub
Study 10 of 41Erythropoietin (EPO) literaturebiorxiv-preprint · Observational2026

Transferrin receptor 1 binds human parvovirus B19 VP1u to facilitate entry

Transferrin receptor 1 (TfR1) has been identified as the receptor that facilitates the entry of human parvovirus B19 into erythroid progenitor cells.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the erythropoietin (epo) corpus
6
Preclinical
26
Observational · this one
1
Open-label
2
Randomised
6
Reviews

Summary and findings

This study investigates the interaction between human parvovirus B19 VP1 unique region (VP1u) and transferrin receptor 1 (TfR1) in erythroid progenitor cells. The research identifies TfR1 as the receptor facilitating B19V entry, confirmed through various binding assays and structural analysis. No therapeutic claims are made.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

Summary Human parvovirus B19 (B19V) exhibits a strict tropism for erythroid progenitor cells, which is governed by the VP1 unique region (VP1u). This region mediates cell-specific uptake by interacting with an unknown cellular receptor, termed VP1uR. Proximity labeling in permissive erythroid cells identified transferrin receptor 1 (TfR1/CD71) as the predominant membrane protein associated with VP1u. VP1u constructs colocalized with TfR1 at the cell surface of erythroid cells. Incubation with anti-TfR1 antibody OKT9 abolished binding and uptake of recombinant VP1u. While OKT9 efficiently inhibited B19V uptake and infection, it did not block virus binding to host cells. Direct binding assays confirmed interaction of VP1u to human TfR1. Using cryoEM we solved the 2.4 Å structure of the TfR1-VP1u complex, mapping the binding site and identifying the specific interactions. These findings establish TfR1 as the previously unknown receptor, VP1uR, required for B19V uptake.

Elsewhere in the Erythropoietin (EPO) corpus

DErythropoietin beyond red blood cells: Systemic and oncological functions (Review).Molecular medicine reports · 2026reviewDSodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.JAMA · 2026 · Hemoglobin changed by 0.55 g/dL in the SGLT2 inhibitor group, P<0.001.reviewBResponsiveness to Erythropoiesis‑Stimulating Agents and Hemoglobin Variability in Japanese Patients With End‑Stage Kidney Diseasebiorxiv-preprint · 2026 · ERI was positively correlated with Hb-RSD (r = 0.473, p = 0.003).HumanBBlood Free Carnitine Level is an Independent Determinant of Erythrocyte Membrane Homogeneity and Osmotic Resistance in Maintenance Hemodialysis Patientsbiorxiv-preprint · 2026 · Higher FC levels were associated with increased OFT slope a (β=0.6090, P=0.036).HumanBGenetic mimicry of haematopoietic growth factor signalling: efficacy–safety trade-offs for cytopenias by drug-target Mendelian randomisationbiorxiv-preprint · 2026 · OR 0.65, 95% CI 0.49–0.86, P=0.0026 for lower thrombocytopenia risk with higher MPL expression.HumanCIn vivo HSPC gene therapy of hemoglobinopathies without drug selection of corrected cellsbiorxiv-preprint · 2026 · >70% HbF-positive erythroid cells in treated miceAnimal